BBBahram Biglari

Bahram Biglari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bahram Biglari has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • A Moghaddam

    Department of Orthopaedics, Trauma and Paraplegiologie, University Hospital Heidelberg, Heidelberg

    2 shared publications
  • H J Gerner

    Department of Orthopaedics, Trauma and Paraplegiologie, University Hospital Heidelberg, Heidelberg

    2 shared publications
  • T Ferbert

    Department of Orthopaedics, Trauma and Paraplegiologie, University Hospital Heidelberg, Heidelberg

    2 shared publications
  • T Swing

    Department of Orthopaedics, Trauma and Paraplegiologie, University Hospital Heidelberg, Heidelberg

    2 shared publications
  • A Büchler

    Department of Orthopaedics, Trauma & Paraplegiologie University Hospital Heidelberg, Heidelberg, Germany

    1 shared publication
  • Alfred Längler

    Department of Paediatric Oncology, Children's Hospital, Herdecke, Germany

    1 shared publication

Latest Publications

  • A retrospective study on flap complications after pressure ulcer surgery in spinal cord-injured patients

    by B Biglari, A Büchler, T Reitzel, T Swing, H J Gerner, T Ferbert, A Moghaddam

    Study design: Objectives: Setting: Methods: Results: Conclusion:


  • Increase in soluble CD95L during subacute phases after human spinal cord injury: a potential therapeutic target

    by B Biglari, A Büchler, T Swing, E Biehl, H J Roth, T Bruckner, G Schmidmaier, T Ferbert, H J Gerner, A Moghaddam

    Study design: A pilot study measuring the levels of serum-soluble CD95 ligand (CD95L) in eight spinal cord-injured patients. Objectives: To determine the soluble concentration of CD95L in spinal cord injury (SCI) patients after trauma. Methods: We collected blood samples from eight patients with acute traumatic SCI. Soluble CD95L serum levels were determined using an enzyme-linked immunosorbent assay. American Spinal Injury Association (ASIA) was determined according to ASIA classification. The patients were monitored, and venous blood was drawn after arrival at the hospital on the 1st and 3rd day and during the 1st, 2nd, 4th, 8th and 12th weeks after trauma. Results: The average patient age was 48.1 years (18–86 years). Three patients were paraplegic (two incomplete, one complete), five were quadriplegic (one complete, four incomplete). The serum concentration of soluble CD95L (sCD95L) decreased during the 1st week (41 ng l−1) and increased after the 2nd week in all eight patients. It peaked during the 4th week (68.5 ng l−1) and reached a plateau during the 12th week (76.2 ng l−1). There are many possible explanations for not being able to detect a statistical significance, one of course being the small sample size. Conclusion: Promising results for anti-CD95L therapy have already been documented in lab studies with rodents. Anti-CD95L blocks the pro-apoptotic and proinflammatory activity of membrane-bound CD95L during the acute phase of SCI. We observed that sCD95L levels are elevated during the subacute and intermediate phases of SCI. It would be of great interest to study a larger group of patients to determine whether higher sCD95 levels are correlated with improved or impaired neurological outcome or with increasing levels of autoimmune components in peripheral blood.


  • Multicentre prospective observational study on professional wound care using honey (Medihoney™)

    by Bahram Biglari, Arash Moghaddam, Kai Santos, Gisela Blaser, Axel Büchler, Gisela Jansen, Alfred Längler, Norbert Graf, Ursula Weiler, Verena Licht, et al.

    In recent years, the treatment of wounds with honey has received an increasing amount of attention from healthcare professionals in Germany and Austria. We conducted a prospective observational multicentre study using Medihoney™ dressings in 10 hospitals – nine in Germany and one in Austria. Wound‐associated parameters were monitored systematically at least three times in all patients. Data derived from the treatment of 121 wounds of various aetiologies over a period of 2 years were analysed. Almost half of the patients were younger than 18 years old, and 32% of the study population was oncology patients. Overall, wound size decreased significantly during the study period and many wounds healed after relatively short time periods. Similarly, perceived pain levels decreased significantly, and the wounds showed noticeably less slough/necrosis. In general, our findings show honey to be an effective and feasible treatment option for professional wound care. In addition, our study showed a relationship between pain and slough/necrosis at the time of recruitment and during wound healing. Future comparative trials are still needed to evaluate the extent to which the positive observations made in this and other studies can definitely be attributed to the effects of honey in wound care.